Product Name: Ros1 (2205-2219)
Product Number: PE-01AVI90
| Size: | 200 µg | Price: | 45.00 | |
| 1 mg | $US | 90.00 | ||
| 5 mg | 211.00 |
Peptide Name: Ros1 (2205-2219)
Product Use: Services as a blocking peptide for use with the Ros-3 rabbit polyclonal antibody (Cat. No.: AB-NK163-4) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CRPTFHRIQDQLQLFR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2057.4 Da
Peptide Purity Percent after Synthesis and Purification: >90
Product Use: Services as a blocking peptide for use with the Ros-3 rabbit polyclonal antibody (Cat. No.: AB-NK163-4) that is also available from Kinexus. The peptide sequence is located in the kinase catalytic domain last alpha-chain.
Peptide Production Method: Solid-phase peptide synthesis
Peptide Origin: Homo sapiens
Peptide Sequence: CRPTFHRIQDQLQLFR
Peptide Modifications N Terminus: Free amino
Peptide Modifications C Terminus: Amide
Peptide Molecular Mass Calculated: 2057.4 Da
Peptide Purity Percent after Synthesis and Purification: >90
Peptide Appearance: White powder
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Ros1 pan-specific antibody (Cat. No.: AB-NK163-4)
Peptide Form: Solid
Storage Conditions: -20°C
Related Product 1: Ros1 pan-specific antibody (Cat. No.: AB-NK163-4)
Scientific Background: Ros (Ros1) is a protein-tyrosine kinase of the TK group and Sev family. It is an orphaned receptor kinase. It has been suggested to activate several downstream signalling pathways in cell differentiation, proliferation, growth and survival including the PI3 kinase-mTOR signalling pathway. Ros1 is highly expressed in several human cancers. A K1980M mutation can lead to impaired phosphotransferase activity, while the mutations Y2274F or Y2334F can lead to loss of phosphorylation and impaired complex formation with PTPN11. It appears to be an oncoprotein (OP). Cancer-related mutations in human tumours point to a gain of function of the protein kinase. The active form of the protein kinase normally acts to promote tumour cell proliferation. Ros is linked to Glioblastoma Multiforme, in which this protein-tyrosine kinase can be constitutively active. This activity can arise either from ROS fusion with the FIG protein or a deletion (q21q21) leading to GOPC-Ros1. Non-small cell lung carcinoma can arise from a SLC34A2-Ros1 fusion expressing the chimeric CD74-Ros1 protein. In non-small cell lung cancer a gain of function has been observed with Mlk1 (MAP3K9), activating ERK downstream. Interestingly, its pattern of diverse mutations in human tumours is actually more characteristic of a tumour suppressor protein.
© Kinexus Bioinformatics Corporation 2017